Pacira BioSciences Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences or view top-rated stocks.

Wall Street analysts have given Pacira BioSciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pacira BioSciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Pacira BioSciences.

Pacira BioSciences will be holding an earnings conference call on Tuesday, August 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "9991311".

Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its quarterly earnings results on Monday, May, 3rd. The company reported $0.53 EPS for the quarter, missing analysts' consensus estimates of $0.64 by $0.11. The company earned $119 million during the quarter, compared to analysts' expectations of $119.23 million. Pacira BioSciences had a trailing twelve-month return on equity of 11.09% and a net margin of 33.35%. Pacira BioSciences's quarterly revenue was up 12.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.53 earnings per share.
View Pacira BioSciences' earnings history.

Pacira BioSciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PCRX stock has increased by 70.7% and is now trading at $60.08.
View which stocks have been most impacted by COVID-19.

Pacira BioSciences issued an update on its second quarter 2021 earnings guidance on Tuesday, July, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135.60 million-$135.60 million, compared to the consensus revenue estimate of $128.01 million.

11 analysts have issued 12-month price objectives for Pacira BioSciences' stock. Their forecasts range from $65.00 to $94.00. On average, they expect Pacira BioSciences' share price to reach $78.31 in the next year. This suggests a possible upside of 30.3% from the stock's current price.
View analysts' price targets for Pacira BioSciences or view top-rated stocks among Wall Street analysts.

54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among Pacira BioSciences' employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Pacira BioSciences include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of PCRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Pacira BioSciences' stock is owned by many different retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.30%), Gradient Investments LLC (0.14%), Legacy Capital Partners Inc. (0.09%), State of Alaska Department of Revenue (0.07%) and Outfitter Financial LLC (0.05%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Donald C Manning, John P Phd Longenecker, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends for Pacira BioSciences.

PCRX stock was sold by a variety of institutional investors in the last quarter, including Outfitter Financial LLC, and Legacy Capital Partners Inc.. Company insiders that have sold Pacira BioSciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Donald C Manning, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences or view top insider-selling stocks.

PCRX stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., Gradient Investments LLC, and State of Alaska Department of Revenue.
View insider buying and selling activity for Pacira BioSciences or or view top insider-buying stocks.

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PCRX stock can currently be purchased for approximately $60.08.

Pacira BioSciences has a market capitalization of $2.65 billion and generates $429.65 million in revenue each year. The company earns $145.52 million in net income (profit) each year or $1.30 on an earnings per share basis.

Pacira BioSciences employs 624 workers across the globe.

The official website for Pacira BioSciences is www.pacira.com.

Pacira BioSciences is headquartered at 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054.

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at (973) 254-3560 or via email at [email protected]